Delcath's liver cancer drug gains FDA orphan-drug status

09/1/2009 | Reuters · Forbes

The FDA granted Delcath Systems' doxorubicin orphan-drug designation as a treatment for primary liver cancer. The company said it plans to further test doxorubicin with its Percutaneous Hepatic Perfusion drug-delivery technology.

View Full Article in:

Reuters · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations